LifeStance Health Group (NASDAQ:LFST) Issues Earnings Results

LifeStance Health Group (NASDAQ:LFST) issued its quarterly earnings data on Thursday. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02, Zacks reports. The firm had revenue of $455.86 million for the quarter, compared to analysts’ expectations of $431.59 million. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The firm’s quarterly revenue was up 25.3% compared to the same quarter last year.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Third-quarter revenue rose 25% to $456 million, driven by 17% growth in visit volume and a 7% increase in revenue per visit. Adjusted EBITDA increased 70% to $68 million, a 15% margin for the second consecutive quarter.
• LifeStance raised its full-year 2026 guidance: revenue to $1.741 billion–$1.761 billion and Adjusted EBITDA to $242 million–$250 million. The midpoint implies 23% revenue growth and roughly 300 basis points of year-over-year margin expansion.
• The clinician base grew 11% to 8,863, with 321 net additions in the quarter; management cited strong recruiting and stable retention. Visits per average clinician rose 5% year over year, which executives attributed partly to improved patient engagement.
• Specialty services revenue is expected to grow about 40% in 2026 to roughly $70 million, with management expecting a similar growth rate next year. The company is gradually expanding TMS and SPRAVATO, while citing positive outcomes data and opportunities to discuss coverage and reimbursement with payers.
• The new EHR rollout is expected to reduce 2027 revenue growth by approximately 1–2 percentage points, putting growth toward the lower end of LifeStance’s long-term mid-teens range. Management also previously estimated implementation costs of $20 million–$30 million; the phased rollout is expected to be completed by year-end 2027.

LifeStance Health Group Price Performance

NASDAQ:LFST traded up $0.34 during mid-day trading on Friday, reaching $13.77. 4,924,487 shares of the company were exchanged, compared to its average volume of 3,459,394. The company has a quick ratio of 1.38, a current ratio of 1.44 and a debt-to-equity ratio of 0.17. The stock has a market cap of $5.26 billion, a PE ratio of 72.48 and a beta of 1.35. LifeStance Health Group has a 12 month low of $5.87 and a 12 month high of $15.66. The company has a fifty day moving average of $12.62 and a 200 day moving average of $9.49.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Canaccord Genuity Group increased their price target on LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. KeyCorp raised their price target on LifeStance Health Group from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Friday. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Insiders Place Their Bets

In other news, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the sale, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares in the company, valued at $1,041,836,942.34. This trade represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 13,777,580 shares of company stock valued at $146,433,781. Insiders own 3.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.